Ravish Singhal
Research Subjects
Ravish Singhal has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Gilda Diaz-Fuentes
Division of Pulmonary and Critical Care Department of Medicine Bronx Care Health System Affiliated with Icahn School of Medicine at Mount Sinai, New York, Bronx, USA
2 shared publications - Gabriella Roa-Gomez
Division of Pulmonary & Critical Care, BronxCare Health System, Bronx, NY 10457, USA
1 shared publication - Olga Alexandra Reyes
Division of Pulmonary & Critical Care, BronxCare Health System, Bronx, NY 10457, USA
1 shared publication - Sindhaghatta Venkatram
Division of Pulmonary and Critical Care Medicine, BronxCare Hospital Center, Bronx, New York, United States. Department of Medicine, BronxCare Hospital Center, Bronx, New York, United States
1 shared publication - Sindhaghatta Venkatram1 shared publication
Latest Publications
- Open Access
- 29 July 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (15) , 3368
Coronavirus Pneumonia: Outcomes and Characteristics of Patients in an Inner-City Area after 3 Months of Infection
Background: The morbidity and long term pulmonary consequences of COVID-19 infection continue to unfold as we learn and follow survivors of this disease. We report radiological evolution and pulmonary function findings in those patients. Methods: This was a retrospective cohort study of adult patients referred to the post-acute COVID-19 pulmonary clinic after a diagnosis of COVID-19 pneumonia. The study period was after the initial peak of the pandemic in New York City, from June to December 2020. Results: 111 patients were included. The average interval time between COVID-19 pneumonia and initial clinic evaluation was 12 weeks. 48.2% of patients had moderate and 22.3% had severe infection. Dyspnea and cough was the most common respiratory symptoms post infection. Radiographic abnormalities improved in majority of patients with ground glass opacities been the common residual abnormal finding. Restrictive airway disease and decreased diffusion capacity were the most common findings in pulmonary function test. Conclusion: Our study suggests the needs for close and serial monitoring of functional and radiological abnormalities during the post COVID-19 period. Considering that many of the clinical-radiological and functional abnormalities are reversible, we suggest a “wait and watch“approach to avoid unnecessary invasive work up.
- 29 July 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (15) , 3368
Open AccessCoronavirus Pneumonia: Outcomes and Characteristics of Patients in an Inner-City Area after 3 Months of Infection
Background: The morbidity and long term pulmonary consequences of COVID-19 infection continue to unfold as we learn and follow survivors of this disease. We report radiological evolution and pulmonary function findings in those patients. Methods: This was a retrospective cohort study of adult patients referred to the post-acute COVID-19 pulmonary clinic after a diagnosis of COVID-19 pneumonia. The study period was after the initial peak of the pandemic in New York City, from June to December 2020. Results: 111 patients were included. The average interval time between COVID-19 pneumonia and initial clinic evaluation was 12 weeks. 48.2% of patients had moderate and 22.3% had severe infection. Dyspnea and cough was the most common respiratory symptoms post infection. Radiographic abnormalities improved in majority of patients with ground glass opacities been the common residual abnormal finding. Restrictive airway disease and decreased diffusion capacity were the most common findings in pulmonary function test. Conclusion: Our study suggests the needs for close and serial monitoring of functional and radiological abnormalities during the post COVID-19 period. Considering that many of the clinical-radiological and functional abnormalities are reversible, we suggest a “wait and watch“approach to avoid unnecessary invasive work up.
- Open Access
- 18 March 2020
- Published by IntechOpen
Advances in Treatment and Outcomes of Patients withLegionellaInfection
Manifestations of Legionella infections range from benign, mild disease to a more severe form with increased morbidity and mortality, especially in untreated patients. Despite diagnostic advances, clinical diagnosis remains elusive. Macrolides and respiratory fluoroquinolones remain the antibiotics of choice for treatment of Legionella; however, several new antibiotics are currently under development or in clinical trials. The recommended duration of antibiotics is 5–7 days; although, some critically ill or immunosuppressed patients may require longer treatment. In vivo resistance to these antibiotics is rare, and there is no evidence that combination therapy is more beneficial than monotherapy. Early suspicion, diagnosis, and treatment are paramount for improving outcomes.
- 18 March 2020
- Published by IntechOpen
Open AccessAdvances in Treatment and Outcomes of Patients withLegionellaInfection
Manifestations of Legionella infections range from benign, mild disease to a more severe form with increased morbidity and mortality, especially in untreated patients. Despite diagnostic advances, clinical diagnosis remains elusive. Macrolides and respiratory fluoroquinolones remain the antibiotics of choice for treatment of Legionella; however, several new antibiotics are currently under development or in clinical trials. The recommended duration of antibiotics is 5–7 days; although, some critically ill or immunosuppressed patients may require longer treatment. In vivo resistance to these antibiotics is rare, and there is no evidence that combination therapy is more beneficial than monotherapy. Early suspicion, diagnosis, and treatment are paramount for improving outcomes.